Hereditary Metabolic Diseases
Disorders of energy metabolism
NCT05164055 – Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
Lipin1 Ko zebrafish
Myoblasts from patients with Lipin 1 deficiency
Tanko2 Ko zebrafish
NCT05564520 – International Multicenter Study on Lipin-1 Deficiency
Lipin1 Ko zebrafish
Myoblasts from patients with Lipin 1 deficiency
Tanko2 Ko zebrafish
NCT05564520 – International Multicenter Study on Lipin-1 Deficiency
Intoxication Diseases
DNA from patients
Fibroblasts from patients
50 patient cohort
NCT04761588 – Evaluation of TYR Sphere in France
Gene therapy
Mice – Bckdh a -/- mouse model
Mice – Bckdh b -/- mouse model
Gene therapy
Gene therapy for Mapple Syrup urine disease
DNA from patients
Fibroblasts from patients
50 patient cohort
Lysosomal storage disorders
NCT05164055 – Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
NCT05222906 – Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05815004 – Guard3: An Open-label Parallel-arm Randomized Controlled Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy AVR-RD-02 Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25
Neurometabolic Disorders
NCT05769621 – A Retrospective Study to Characterize Participants With Propionic Acidemia
Secondary to metabolic disease
Patient cohort
NCT04674761 – Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
NCT05035030 – Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Glycosylation congenital disorders
Cerebellum specific Srd5a3 KO mice